With the global economy growing faster than ever, CEOs are increasingly making billions in salaries, but the median pay of CEOs is still well below the median worker.
For the first time in nearly two decades, the average salary for CEOs is $1.8 million less than that of their workers.
In 2016, the median salary for workers was $28,000, while the median compensation of CEOs was $8.2 million, according to a new report from the Institute for Policy Studies (IPS).
The median salary of a CEO of a multinational pharmaceutical company was $3.8 billion, compared to the $5.6 billion for all workers.
This year, the ILS expects that the top 1 percent of U.S. companies will be worth $1 trillion, up from $850 billion in 2017, thanks in part to pharmaceutical spending.
But despite this increase, CEOs at the world’s largest pharmaceutical companies earn an average salary of $1,300,000.
This was a huge gap, with CEOs at some of the largest companies earning more than a half-million dollars a year.
As CEO pay has exploded, so too has their compensation.
For example, the CEO of the pharmaceutical company Johnson & Johnson earned $5 million last year.
The average CEO of Johnson &amassives made $1 million, or about $18,000 more than the average worker.
That’s because Johnson &ammassives is worth $4.4 billion, while most U.K. pharmaceutical companies were worth just $5 billion.
But it’s not just the pay that’s out of whack.
According to IPS, CEOs also take more of the country’s tax revenues, and as a result, pay out more in benefits.
In 2017, CEOs made about $1 billion more in bonuses than the typical worker, according a report released last year by the AFL-CIO.
This means CEOs take more in retirement, Social Security and other benefits than workers do, according the report.
The report also shows that CEOs of multinational pharmaceutical companies took in $5,000 per person, while workers earned $3,000 in wages.
That means CEOs of these companies received $20 billion in tax cuts from 2017 to 2024, and $17.3 billion in annual benefits, according at the time.
But CEOs of the rest of the companies were left out of the conversation, according an analysis by the Center for Responsive Politics, which tracked all of the corporate income tax filings for 2016.
The Center found that, despite their massive profits, most companies pay a fraction of the tax they owe, at least $3 billion.
So while CEOs of major pharmaceutical companies can make millions, the rest have little money to show for it.